[go: up one dir, main page]

WO2009088220A3 - Diamide nicotinate n,n-diméthyl imidodicarbonimidique, son procédé de production et composition pharmaceutique le comprenant - Google Patents

Diamide nicotinate n,n-diméthyl imidodicarbonimidique, son procédé de production et composition pharmaceutique le comprenant Download PDF

Info

Publication number
WO2009088220A3
WO2009088220A3 PCT/KR2009/000071 KR2009000071W WO2009088220A3 WO 2009088220 A3 WO2009088220 A3 WO 2009088220A3 KR 2009000071 W KR2009000071 W KR 2009000071W WO 2009088220 A3 WO2009088220 A3 WO 2009088220A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
pharmaceutical composition
imidodicarbonimidic diamide
dimethyl imidodicarbonimidic
nicotinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/000071
Other languages
English (en)
Korean (ko)
Other versions
WO2009088220A2 (fr
Inventor
김성욱
전성수
조영관
구자성
김영웅
김병하
강민석
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanall Pharmaceutical Co Ltd
Original Assignee
Hanall Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Pharmaceutical Co Ltd filed Critical Hanall Pharmaceutical Co Ltd
Publication of WO2009088220A2 publication Critical patent/WO2009088220A2/fr
Publication of WO2009088220A3 publication Critical patent/WO2009088220A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouveau sel d'acide nicotinique de diamide N,N -diméthyl imidodicarbonimidique, son procédé de préparation et une composition pharmaceutique le contenant. Elle concerne, plus particulièrement, un sel d'acide nicotinique de diamide N,N- diméthyl imidodicarbonimidique, qui présente des propriétés chimiques et physiques améliorées, notamment des propriétés de solubilité, de stabilité, de non-hygroscopicité et anti-adhésives, ainsi qu'une faible toxicité, et qui se révèle donc très efficace dans la prévention et le traitement non seulement du diabète et de ses complications chez des patients souffrant de ce que l'on appelle communément syndromes métaboliques, chez qui le diabète, l'obésité, l'hyperlipidémie, la stéatose hépatique, des maladies coronariennes, l'ostéoporose, des syndromes des ovaires polykystiques, etc. apparaissent en combinaison, mais aussi des cancers à déficit de gène p53, des douleurs musculaires, la cytotoxicité musculaire et la rhabdomyolyse. L'invention concerne également un procédé de préparation de ce composé et une composition pharmaceutique le contenant.
PCT/KR2009/000071 2008-01-08 2009-01-07 Diamide nicotinate n,n-diméthyl imidodicarbonimidique, son procédé de production et composition pharmaceutique le comprenant Ceased WO2009088220A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080002118 2008-01-08
KR10-2008-0002118 2008-01-08

Publications (2)

Publication Number Publication Date
WO2009088220A2 WO2009088220A2 (fr) 2009-07-16
WO2009088220A3 true WO2009088220A3 (fr) 2009-09-03

Family

ID=40853597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/000071 Ceased WO2009088220A2 (fr) 2008-01-08 2009-01-07 Diamide nicotinate n,n-diméthyl imidodicarbonimidique, son procédé de production et composition pharmaceutique le comprenant

Country Status (2)

Country Link
KR (1) KR101104912B1 (fr)
WO (1) WO2009088220A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
WO2025122954A1 (fr) 2023-12-08 2025-06-12 Battelle Memorial Institute Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2357864A1 (de) * 1973-06-01 1974-12-19 Hurka Wilhelm Nicotinsaure salze von derivaten des biguanids, verfahren zu ihrer herstellung, sowie diese salze enthaltende arzneimittel
US4028402A (en) * 1974-10-11 1977-06-07 Hoffmann-La Roche Inc. Biguanide salts
US4835184A (en) * 1985-07-31 1989-05-30 Albert Rolland Sa Novel pharmaceutical compositions intended to the treatment of neuropathies and promoting the nervous regeneration
US6031004A (en) * 1997-12-08 2000-02-29 Bristol-Myers Squibb Company Salts of metformin and method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2357864A1 (de) * 1973-06-01 1974-12-19 Hurka Wilhelm Nicotinsaure salze von derivaten des biguanids, verfahren zu ihrer herstellung, sowie diese salze enthaltende arzneimittel
US4028402A (en) * 1974-10-11 1977-06-07 Hoffmann-La Roche Inc. Biguanide salts
US4835184A (en) * 1985-07-31 1989-05-30 Albert Rolland Sa Novel pharmaceutical compositions intended to the treatment of neuropathies and promoting the nervous regeneration
US6031004A (en) * 1997-12-08 2000-02-29 Bristol-Myers Squibb Company Salts of metformin and method

Also Published As

Publication number Publication date
KR20090076827A (ko) 2009-07-13
KR101104912B1 (ko) 2012-01-12
WO2009088220A2 (fr) 2009-07-16

Similar Documents

Publication Publication Date Title
WO2009038396A3 (fr) Diamide dicarboxylate n, n- diméthyl imidodicarbonimidique, son procédé de production et compositions pharmaceutiques le comprenant
EP1698624A4 (fr) Derives d'acide phenylpropanoique
WO2011083999A3 (fr) Dérivé de biguanide, son procédé de préparation, et composition pharmaceutique contenant ce dérivé en tant que principe actif
WO2016105118A3 (fr) Dérivé de biaryle utilisable en tant qu'agoniste du gpr120
JP2008521829A5 (fr)
JP2008521831A5 (fr)
JP2009530399A5 (fr)
WO2009088220A3 (fr) Diamide nicotinate n,n-diméthyl imidodicarbonimidique, son procédé de production et composition pharmaceutique le comprenant
WO2009002427A3 (fr) Procédés de synthèse du cinacalcet et de ses sels
WO2008040548A3 (fr) Traitement pour l'hépatite stéatosique non alcoolique
HK1222658A1 (zh) 氰基三唑化合物
WO2006128056A3 (fr) Nouvelles substances thyromimetiques contenant de l'acide phosphinique
WO2010094126A8 (fr) Dérivés hétérocycliques comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
JO3813B1 (ar) أحماض دهنية جديدة واستخدامها بالاقتران مع جزيئات حيوية
CY1122742T1 (el) Διαρυλ παραγωγα ως αγωνιστες gpr120
WO2004113270A3 (fr) Derives carboxyliques
WO2009087212A3 (fr) Composés organiques
TW200628154A (en) Organic compounds
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
WO2010003624A3 (fr) Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
EP1784388B8 (fr) Derivés d'acide biphényloxyacétique pour le traitement de la maladie respiratoire
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
MX2010003603A (es) Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida.
WO2006128055A3 (fr) Nouvelles substances thyromimetiques contenant du phosphore
MY139107A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09701355

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09701355

Country of ref document: EP

Kind code of ref document: A2